Intranodal delivery of modified docetaxel: Innovative therapeutic method to inhibit tumor cell growth in lymph nodes. Issue 4 (14th February 2022)

• Record Type: Journal Article
• Authors: Sukhbaatar, Ariunbuyan; Mori, Shiro; Kodama, Tetsuya
• Is Part Of: Cancer science. Volume 113:Issue 4(2022)
• Page Start: 1125
• Page End: 1139
• Publication Date: 2022-02-14
• Subjects: docetaxel -- drug delivery -- lymph node metastasis -- osmotic pressure -- viscosity; Cancer -- Periodicals; Neoplasms -- Periodicals; Research -- Periodicals; Electronic journals; 616.994005
• DOI: 10.1111/cas.15283
• Languages: English
• ISSNs: 1347-9032

Abstract

Abstract: Delivery of chemotherapeutic agents into metastatic lymph nodes (LNs) is challenging as they are unevenly distributed in the body. They are difficult to access via traditional systemic routes of drug administration, which produce significant adverse effects and result in low accumulation of drugs into the cancerous LN. To improve the survival rate of patients with LN metastasis, a lymphatic drug delivery system (LDDS) has been developed to target metastatic LN by delivering chemotherapy agents into sentinel LN (SLN) under ultrasound guidance. The LDDS is an advanced method that can be applied in the early stage of the progression of tumor cells in the SLN before tumor mass formation has occurred. Here we investigated the optimal physicochemical ranges of chemotherapeutic agents' solvents with the aim of increasing treatment efficacy using the LDDS. We found that an appropriate osmotic pressure range for drug administration was 700–3, 000 kPa, with a viscosity < 40 mPa⋅s. In these physicochemical ranges, expansion of lymphatic vessels and sinuses, drug retention, and subsequent antitumor effects could be more precisely controlled. Furthermore, the antitumor effects depended on the tumor progression stage in the SLN, the injection rate, and the volumes of administered drugs. We anticipate these optimal ranges to be a starting point for developing more effective drug regimens to treat metastatic LN with the LDDS. Abstract : Lymph node metastasis targeted LDDS uses a low concentration of chemotherapy agents, resulting in higher treatment outcomes with fewer side effects. We found that an appropriate osmotic pressure range for drug administration was 700–3, 000 kPa, with a viscosity < 40 mPa⋅s.